专家会议报告：制定欧洲联合路线图，以满足接受生物治疗的儿童哮喘患者未被满足的需求和优先事项。
Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy.
作者信息
Golebski Korneliusz, Dankelman Lente H M, Björkander Sofia, Bønnelykke Klaus, Brinkman Paul, Deschildre Antoine, van Dijk Yoni E, Fleming Louise, Grigg Jonathan, Hamelmann Eckard, Hashimoto Simone, Kabesch Michael, Klevebro Susanna, Maitland-van der Zee Anke-Hilse, Merid Simon K, Nieto Antonio, Niggel Jakob, Nilsson Caroline, Potočnik Uroš, Roberts Graham, Rusconi Franca, Saglani Sejal, Valente Elisangela, van Drunen Cornelis, Wang Gang, Melén Erik, Vijverberg Susanne J H
机构信息
Dept of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Dept of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
出版信息
ERJ Open Res. 2021 Nov 1;7(4). doi: 10.1183/23120541.00381-2021. eCollection 2021 Oct.
Abstract
相似文献
1
Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy.专家会议报告：制定欧洲联合路线图，以满足接受生物治疗的儿童哮喘患者未被满足的需求和优先事项。
ERJ Open Res. 2021 Nov 1;7(4). doi: 10.1183/23120541.00381-2021. eCollection 2021 Oct.
2
A research roadmap for complementary and alternative medicine - what we need to know by 2020.补充和替代医学研究路线图——到2020年我们需要了解的内容。
Forsch Komplementmed. 2014;21(2):e1-16. doi: 10.1159/000360744. Epub 2014 Mar 24.
3
Clinical and research priorities for children and young people with bronchiectasis: an international roadmap.支气管扩张症儿童和青少年的临床与研究重点：一份国际路线图。
ERJ Open Res. 2021 Jul 19;7(3). doi: 10.1183/23120541.00122-2021. eCollection 2021 Jul.
4
A survey of specialist opinions on biomarker use in severe asthma in Australia: scepticism but hope?澳大利亚关于生物标志物在重度哮喘中应用的专家意见调查：怀疑但仍有希望？
ERJ Open Res. 2020 May 26;6(2). doi: 10.1183/23120541.00113-2020. eCollection 2020 Apr.
5
First analysis of the Severe Paediatric Asthma Collaborative in Europe registry.欧洲儿童重症哮喘协作登记处的首次分析。
ERJ Open Res. 2020 Nov 2;6(4). doi: 10.1183/23120541.00566-2020. eCollection 2020 Oct.
6
Severe asthma patients' and physicians' perspectives of disease burden: do they match?重度哮喘患者和医生对疾病负担的看法：二者是否一致？
ERJ Open Res. 2023 May 30;9(3). doi: 10.1183/23120541.00177-2023. eCollection 2023 May.
7
Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.溃疡性结肠炎未满足的医疗需求：专家组共识
Dig Dis. 2019;37(4):266-283. doi: 10.1159/000496739. Epub 2019 Feb 6.
8
Unmet Needs in Ophthalmology: A European Vision Institute-Consensus Roadmap 2019-2025.眼科学未满足的需求：欧洲视觉研究所 2019-2025 年共识路线图。
Ophthalmic Res. 2019;62(3):123-133. doi: 10.1159/000501374. Epub 2019 Aug 5.
9
Critical Care Network in the State of Qatar.卡塔尔国重症监护网络。
Qatar Med J. 2019 Nov 7;2019(2):2. doi: 10.5339/qmj.2019.qccc.2. eCollection 2019.
10
Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series.严重哮喘中与抗白细胞介素-5治疗相关的关节表现：病例系列
ERJ Open Res. 2024 Feb 26;10(1). doi: 10.1183/23120541.00935-2023. eCollection 2024 Jan.
引用本文的文献
1
Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK.英国儿童哮喘的临床负担与医疗资源利用情况
J Asthma Allergy. 2025 Feb 6;18:161-171. doi: 10.2147/JAA.S452747. eCollection 2025.
2
Unanswered questions on the use of biologics in pediatric asthma.关于生物制剂在儿童哮喘治疗中应用的未解决问题。
World Allergy Organ J. 2023 Nov 3;16(11):100837. doi: 10.1016/j.waojou.2023.100837. eCollection 2023 Nov.
3
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.儿童和青少年重症哮喘管理的新进展：聚焦度普利尤单抗和特泽鲁单抗。
Paediatr Drugs. 2023 Nov;25(6):677-693. doi: 10.1007/s40272-023-00589-4. Epub 2023 Sep 2.
4
Definitions of non-response and response to biological therapy for severe asthma: a systematic review.重度哮喘生物治疗无反应和反应的定义：一项系统评价
ERJ Open Res. 2023 May 2;9(3). doi: 10.1183/23120541.00444-2022. eCollection 2023 Jul.
5
Asthma in paediatric intensive care in England residents: observational study.英国儿科重症监护病房哮喘患儿：观察性研究。
Sci Rep. 2022 Jan 25;12(1):1315. doi: 10.1038/s41598-022-05414-5.
本文引用的文献
1
Paediatric severe asthma biologics service: from hospital to home.儿科严重哮喘生物制剂服务：从医院到家庭。
Arch Dis Child. 2021 Sep;106(9):900-902. doi: 10.1136/archdischild-2020-320626. Epub 2021 Feb 15.
2
First analysis of the Severe Paediatric Asthma Collaborative in Europe registry.欧洲儿童重症哮喘协作登记处的首次分析。
ERJ Open Res. 2020 Nov 2;6(4). doi: 10.1183/23120541.00566-2020. eCollection 2020 Oct.
3
Adolescents' experiences with patient engagement in respiratory medicine.青少年在呼吸医学中参与患者的体验。
Pediatr Pulmonol. 2021 Jan;56(1):211-216. doi: 10.1002/ppul.25150. Epub 2020 Nov 9.
4
Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation.抗白细胞介素-5 生物制剂治疗重度哮喘的长期疗效：真实世界评估。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1194-1200. doi: 10.1016/j.jaip.2020.10.010. Epub 2020 Oct 15.
5
Advances in understanding and reducing the burden of severe asthma in children.深入了解并减轻儿童重度哮喘负担的进展。
Lancet Respir Med. 2020 Oct;8(10):1032-1044. doi: 10.1016/S2213-2600(20)30399-4. Epub 2020 Sep 7.
6
Single-Cell and Population Transcriptomics Reveal Pan-epithelial Remodeling in Type 2-High Asthma.单细胞和群体转录组学揭示 2 型高反应性哮喘的全上皮重塑。
Cell Rep. 2020 Jul 7;32(1):107872. doi: 10.1016/j.celrep.2020.107872.
7
Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma.奥马珠单抗治疗儿童、青少年及成人重度过敏性哮喘的疗效：一项系统评价、荟萃分析及呼吁采用当前重度哮喘评估指南开展新试验
Allergy Asthma Clin Immunol. 2020 Jun 18;16:49. doi: 10.1186/s13223-020-00442-0. eCollection 2020.
8
Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden.新冠疫情对儿童哮喘的影响：实践调整和疾病负担。
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2592-2599.e3. doi: 10.1016/j.jaip.2020.06.001. Epub 2020 Jun 17.
9
Childhood asthma heterogeneity at the era of precision medicine: Modulating the immune response or the microbiota for the management of asthma attack.精准医学时代的儿童哮喘异质性：调节免疫反应或微生物群以管理哮喘发作。
Biochem Pharmacol. 2020 Sep;179:114046. doi: 10.1016/j.bcp.2020.114046. Epub 2020 May 22.
10
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.生物制剂（贝那利珠单抗、度普利尤单抗、美泊利单抗、奥马珠单抗和瑞利珠单抗）治疗重度嗜酸性粒细胞性哮喘的疗效和安全性。EAACI指南的系统评价——关于生物制剂在重度哮喘中应用的建议
Allergy. 2020 May;75(5):1023-1042. doi: 10.1111/all.14221. Epub 2020 Feb 24.
Zotero 插件